Nifty22,808.5095.41
Sensex73,582.53262.98
Trent3,785.00234.41
Gold (MCX) (Rs/10g.)149,778.0098.00
USD/INR92.85-0.26
Market Watch

Adar Poonawalla

CEO, Serum Institute of India

Birth DetailsJanuary 14, 1981

NationalityIndian

LeagueBusiness Leader

EducationGraduate, University of Westminster, London

Adar Poonawalla's Assets:

Stake in SII
Rising Sun Holdings Ltd (RSHPL

Adar Poonawalla's Journey so far ...

After completing his schooling at the Bishop's School in Pune, Adar Poonawalla went to England for higher studies. In 2001, he graduated from the University of Westminster in London
He came back from England after graduation and joined the Serum Institute of India (SII), founded by his father Cyrus Poonawalla in 1966. The first role he took up was to focus on exporting the company's products
He was appointed as CEO of SII in 2011 and within four years, the vaccine maker's products were being exported to around 140 countries
Under his leadership, SII acquired Netherlands-based Bilthoven Biologicals and soon became the world's biggest vaccine producer
In 2014, the Pune-based businessman launched SII's oral polio vaccine which helped in overcoming a global shortage
Poonawalla came into the limelight in 2020 when the world and India were battling Covid-19. He led SII in tying up with AstraZeneca to manufacture its vaccine which the Anglo-Swedish drugmaker developed with the Oxford University
Poonawalla is spearheading the production of millions of doses of Covishield, a licensed version of the AstraZeneca vaccine, which is India's most used Covid vaccine
He also led SII in tying up with American vaccine maker Novavax to produce 2 billion doses of Covid-19 vaccine
In early 2021, Adar Poonawalla-controlled Rising Sun Holdings Ltd (RSHPL) bought a majority stake in shadow lender Magma Fincorp which operates in retail finance, SME finance, housing finance and general insurance business. The deal was valued at around $475 million
Later in 2021, Magma Fincorp appointed him as chairman of the company
The head of SII transferred his entire stake in Panacea Biotec, worth Rs 118 cr, to Serum Institute in May 2021. The company is known for contract manufacturing in the pharma sector and is involved in manufacturing of both human and animal vaccines
In 2021, he announced that SII would invest $334 million in the United Kingdom to grow its vaccine business and create jobs
Poonawalla raised his voice against the US ban on the export of critical raw materials used in the manufacture of vaccines; the ban has since been overturned
He created a flutter when he told a London-based newspaper that he was getting constant threats and pressure from “powerful people” seeking vaccine doses on priority
The central government granted Y category security to the Pune-based industrialist

Before you go ...

Adar Poonawalla rented his London mansion earlier in 2021 for $69,000 a week, a Mayfair record
India's vaccine hero was awarded The Economic Times Entrepreneur of The Year award in 2020
In 2015, he started the Clean City Initiative in his home city of Pune to improve waste management and environment
Belonging to one of the world's richest families, Adar keenly takes part in philanthropy. He started the Villoo Poonawalla Foundation in 2011 in memory of his late mother Villoo Poonawalla, which runs schools and hospitals
Prime Minister Narendra Modi has appointed him as one of the brand ambassadors of the Swachh Bharat Mission

Last Updated: 26/07/2021

Adar Poonawalla News

Rajasthan Royals sold for $1.65B to Mittal-Poonawalla consortium
A consortium led by the Mittal family and including Adar Poonawalla will acquire Rajasthan Royals for $1.65 billion. The Mittal family will hold a majority stake. This deal follows a previous failed sale. The transaction includes overseas franchises. Approvals are pending, with closure expected in the third quarter of 2026. New investors will join the board.
‘IPL in safest hands’: Lalit Modi backs Mittal-Poonawalla takeover of Rajasthan Royals
The Mittal family, in partnership with Adar Poonawalla, is set to acquire a controlling stake in Rajasthan Royals. This significant deal values the franchise at around $1.65 billion. The acquisition includes the team's global footprint. Existing investors will retain a small stake. The transaction is expected to close in the third quarter of 2026, pending regulatory approvals.
Mittal family-led consortium to acquire Rajasthan Royals in $1.65 billion deal
The Mittal family, led by Lakshmi N. Mittal and Aditya Mittal, is set to acquire a significant 75% stake in the Rajasthan Royals franchise. This deal, valued at approximately $1.65 billion, includes associated global teams. Adar Poonawalla will hold an 18% stake. The transaction is anticipated to conclude in the third quarter of 2026, pending necessary approvals.
Mittal family set to own 75% of Rajasthan Royals in $1.65 billion deal
The Mittal Family and Adar Poonawalla are set to acquire a controlling stake in the Rajasthan Royals IPL franchise. The deal values the team at approximately $1.65 billion. This significant acquisition includes ownership of associated teams in South Africa and the Caribbean. The transaction is anticipated to finalize in the third quarter of 2026.
Svasti Microfinance raises Rs 47.5 crore
Adar Poonawalla-backed Svasti Microfinance secured ₹47.5 crore from key investors, including Abler Nordic and Rajiv Dadlani Group. This funding, a mix of equity and debt, will fuel expansion of its loan portfolio, bolster digital infrastructure, and broaden product offerings beyond joint liability loans. Svasti targets ₹1,400 crore in assets under management by March 2027.
Natasha Poonawalla’s Most Jaw-Dropping Looks Ever
Business leader Adar Poonawalla’s wife, Natasha Poonawalla, is a masterclass in audacity, blending couture, craftsmanship, and creativity to create looks that command global attention.
Dharma Productions buys out Cornerstone stake in talent venture, rebrands agency as DCAA
Dharma Productions has acquired Cornerstone's stake in its talent management arm. The company is now Dharma Collab Artists Agency, or DCAA. This new agency will represent talent across film, music, sports, digital media, and live entertainment. Uday Singh Gauri will continue as CEO.
Billionaires eye RCB as Diageo reviews investment: Nikhil Kamath, Ranjan Pai, Poonawalla are potential bidders
Other big names that have indicated interest in acquiring RCB include a US-based PE firm, Adani Group, JSW Group led by the Jindal family, and Ravi Jaipuria of Devyani International Group.
Dharma Productions absorbs Dharmatic Entertainment in structural overhaul
Dharma Productions is consolidating its operations by merging its digital arm, Dharmatic Entertainment, into the parent company, effective April 1, 2025. This strategic move, following a major investment from Adar Poonawalla, aims to streamline the group structure, reduce overheads, and enhance efficiency in an evolving entertainment landscape. Dharmatic, a wholly-owned subsidiary, focused on creating content for streaming platforms.
Adar Poonawalla hints at purchasing stake in RCB with a cryptic social media post
Serum Institute CEO Adar Poonawalla has shown interest in acquiring a stake in IPL franchise Royal Challengers Bangalore (RCB), owned by United Spirits. His comments follow RCB’s maiden IPL win under Rajat Patidar and a tragic stampede incident in June. Former IPL commissioner Lalit Modi called RCB a prime investment opportunity, with potential interest from global or sovereign funds.
Vidal Health and Serum Institute collaborate on HPV vaccine access
Vidal Health, in partnership with Serum Institute of India, will launch a digital platform on October 1, 2025, to streamline HPV vaccine access and promote cervical cancer prevention. The platform offers convenient appointment booking, digital consent, and certification, ensuring a cashless and paperless experience. This collaboration aims to improve vaccine delivery efficiency and awareness, supporting national healthcare efforts.
Overseas luxury real estate: Here’s why it is catching the eyes of HNIs
Overseas luxury real estate is a high-involvement play. It demands due diligence, regulatory awareness, and trusted local partnerships. Done right, a home abroad can be more than a financial asset. It becomes a gateway to global living, future-proofing one’s wealth, and passing on a legacy with international roots.
Magma sells general insurance business to Patanjali, DS Group
Baba Ramdev's Patanjali Ayurved, along with Dharampal Satyapal Group, has acquired a majority stake in Magma General Insurance from Sanoti Properties, valuing the insurer at ₹4,500 crore. This deal signifies Patanjali's expansion into the general insurance market and broader financial services sector.
Strategy is to first serve India's vaccine needs and then move on to exports, says Adar Poonawalla
Serum Institute of India is planning to introduce chikungunya and monkeypox vaccines in about a year and a half and a dengue vaccine in approximately three years. The company is focusing on vaccine development and aims to supply new vaccines globally after meeting India's needs. The investment in Karan Johar's Dharma Productions reflects their broader strategic interests.
Sunday turns into 'stareday' as industrialists, netizens collaborate to hit back at '90-hour work week' debate
L&T Chairman SN Subrahmanyan's call for a 90-hour work week sparked widespread online mockery and humorous reactions. Prominent figures like SII's Adar Poonawalla and Mahindra Group's Anand Mahindra responded with witty comments, while others joined the conversation with playful social media posts, highlighting the ongoing work-life balance debate.
Adar Poonawalla, CEO of Serum Institute of India, says his wife Natasha loves staring at him on Sundays
The work-life balance debate intensified as RPG Group Chairman Harsh Goenka humorously suggested renaming Sunday as “Sun-duty” on social media. Emphasizing the pitfalls of excessive work hours, he warned against burnout and declared, “Work-life balance isn’t optional; it’s essential for sustained success and well-being.”
JetSynthesys plans to list in next three years
JetSynthesys, backed by Adar Poonawalla and Sachin Tendulkar, may go public within 18-36 months to fund expansion. The company targets 20-fold growth in gaming, entertainment, and wellness sectors. It recently invested $4.5 million in Saudi game developer UMX Studio and launched the Global eCricket Premier League, aiming to combine cricket, gaming, and entertainment.
ET Exclusive: Serum Institute's Aadar Poonawala to acquire 50% of Karan Johar’s Dharma Productions for Rs 1000 cr
Billionaire Adar Poonawalla, CEO of Serum Institute of India, is set to invest Rs 1000 crore for a 50% stake in Karan Johar's Dharma Production and Dharmatic Entertainment. The partnership aims to leverage Poonawalla's financial muscle to cater to digitally savvy consumers and expand content for global platforms.
Adar Poonawalla’s Rising Sun Holdings buys office space in Pune for Rs 395 crore
Rising Sun Holdings, co-owned by Adar Cyrus Poonawalla, has acquired a large office space in Pune's Hinjewadi IT hub for Rs 395 crore. The purchase includes four floors of Cerebrum IT Park, covering 2.2 lakh sq ft. This acquisition is part of Rising Sun Holdings' expanding real estate portfolio.
Sonam Kapoor’s father-in-law buys $27 million London home
Sonam Kapoor's father-in-law and Indian tycoon Harish Ahuja has purchased a £21 million home in London's Notting Hill. The property, which spans over 20,000 square feet, will be partially redeveloped for his son Anand Ahuja and daughter-in-law Sonam Kapoor. This deal is among the few high-value transactions in London's luxury real estate market this year.
Mpox vaccine coming soon, says Covishield manufacturer SII's CEO Adar Poonawalla
Mpox Vaccine: Adar Poonawalla of the Serum Institute of India announced that the company was developing a Mpox vaccine, with results expected within a year. The government issued isolation guidelines for suspected cases, and the NIV in Pune tested samples. Experts highlighted concerns about the new CLADE 1B lineage but did not foresee a lockdown.
Serum Institute says working to develop Monkeypox vaccine
The World Health Organisation on August 14 declared the Mpox outbreak a public health emergency of international concern. The move came after a sudden increase in cases was recorded in parts of Africa. In India, around 30 Mpox cases have been detected since 2022. The most recent case in the country was reported in March 2024.
SII, the world’s largest vaccine maker, sees demand doubling in five years
Serum Institute of India Pvt. is gearing up to meet the growing demand for life-saving vaccines, with expectations to double sales in the next five years. The world's largest vaccine maker, based in Pune, currently has the capacity to produce 3 billion doses annually but only sells about half of that. CEO Adar Poonawalla is optimistic about the increasing uptake of vaccines globally as countries boost their healthcare budgets.
Serum Partners US company to advance needle-free injection technology
SII said, in a statement on Friday that the partnership with IntegriMedical aligns with its vision of 'Health for All' and IntegriMedical's mission to 'transform healthcare globally' by providing patient comfort, ensuring increased patient compliance, reducing needle-stick injuries, and enhancing the efficacy of liquid medication via needle-free dispersion.
Serum Institute buys 20% stake in IntegriMedical
Serum Institute of India acquires 20% stake in IntegriMedical for N-FIS drug delivery solution. Adar Poonawalla envisions a needle-free vaccine administration. N-FIS has regulatory approvals and patented technology. Available in the Indian private market, it eliminates needle-phobia and prevents injuries.
There can't be shortage of Polio vaccine; Serum Institute can make it: CEO Adar Poonawalla
Pune-based Serum Institute of India (SII) is prepared to increase production of injectable poliomyelitis vaccine (IPV) to fill the gap left by France's Sanofi closing its manufacturing plants in India. SII currently supplies half of the 20 million IPV doses to the government's immunization program and can provide additional doses with a 3-4 month notice. Adar Poonawalla, SII CEO, stated that supplying IPV to the government at current prices is unviable for most companies, but SII continues to do so as a service to the nation.
Arvind Kapil named CEO of Poonawalla Fincorp
Arvind Kapil is currently the group head mortgage banking business at the bank which includes home loans, loans against property (LAP) and the sales business of the erstwhile Housing Development Finance Corp (HDFC) which was merged with the bank last year.
#BoycottMaldives trends post diplomatic storm
X user Rushik Rawal shared a screenshot and wrote that he had a three weeks booking worth Rs 5 lakh from February 1at Palms Retreat, Fulhadhoo in Maldives. "Cancelled immediately after their ministers being racists," he stated. Another user on X, Dr Falak Joshipura also shared some screenshots and wrote she was planning to go to Maldives for her birthday which falls on February 2. "Had almost finalised the deal with my travel agent, but immediately cancelled it after seeing this tweet of deputy minister of Maldives," she stated and added the hashtag boycott Maldives.
Natasha Poonawalla's Diwali a starry-sequinned-shimmery one, starring Rishi Sunak and Priyanka Chopra!
The Chairperson of Serum Life Sciences UK thanked Sunak for the growing support and encouragement.
Serum Institute CEO Adar Poonawalla expects malaria vaccine supply-demand mismatch to end in 2024
"We're expecting a final WHO approval in the coming months, after which we can roll it out," Poonawalla told Reuters in an interview, adding that the company had already produced more than 20 million doses of product in anticipation of the clearance.
Cyrus Poonawalla Group appoints Keki Mistry as advisor for financial services ventures
Keki Mistry, former CEO and vice chairman of HDFC, has been appointed as an advisor for Cyrus Poonawalla Group's financial services ventures, headed by Adar Poonawalla. Cyrus Poonawalla Group operates across various sectors including Pharmaceuticals & Biotechnology, Finance, Clean Energy, Hospitality, Realty, and Aviation. Adar Poonawalla expressed confidence in Mistry's financial services sector expertise and believed he would provide a sounding board to management teams while they scale their profitability through risk management in an uncertain business environment.
Serum Institute's multivalent meningococcal meningitis vaccine gets WHO prequalification
The Serum Institute of India (SII), world's largest vaccine maker by volumes on Wednesday said its vaccine to protect against the five predominant causes of meningococcal meningitis in Africa has been prequalified by the World Health Organisation (WHO), making the vaccine eligible to be procured by United Nations agencies and Gavi, the Vaccine Alliance.
The mighty 7! Serum Institute, NSE among India's top unlisted companies
Adar Poonawalla-helmed Serum Institute of India (SII) is India’s most valuable unlisted company, according to the Burgundy Private Hurun India 500 list
Co-living is shifting towards luxury & premium offerings: Housr CEO
The co-living market in India is set to exceed $1bn by 2025, driven by a growing millennial population, according to Makreo Research. Housr is among the startups benefitting from the trend and has ambitious plans to expand, bolstered by several investors including Adar Poonawalla, CEO of Serum Institute of India. The firm operates on an asset-light model, leasing properties on a long-term basis in multiple cities, where it offers a range of services, such as laundry and housekeeping, for renters. Housr's margins are around 20-22%.
Zydus picks 6.5% in Mylab from Adar Poonawala co for ₹106 Cr
Mylab came into limelight during Covid pandemic when it developed and launched indigenous RT-PCR test kits and platform for diagnosing Covid.
We are focusing on becoming efficient and profitable: Adar Poonawalla
Well right now I have been focusing on becoming efficient and profitable. You have seen our profits grow quite well and it is more than Rs 500 crores in the last year ending and we started off with a loss of Rs 600 crores.
Current Covid strain mild, SII has produced 5-6 million Covovax doses: Adar Poonawalla
India has recorded 12,193 fresh Covid-19 cases in a span of 24 hours, with the number of active cases of the infection going up to 67,556, the Union health ministry said on Saturday.
Oxford University, Serum Institute of India tie-up delivers 'high efficacy' malaria vaccine
The R21/Matrix-M vaccine, leveraging Novavax's adjuvant technology, has been approved for use in children aged 5 to 36 months - the age group at the highest risk of death from malaria. It marks the first regulatory clearance for the R21/Matrix-M malaria vaccine for use in any country.
Serum Institute of India restarts manufacturing of COVID-19 vaccine Covishield
Adar Poonawalla further said Serum Institute of India (SII) will make 6-7 million doses of Covishield available in 90 days and it could take up to nine months to further build up the stock based on demand.
Serum Institute of India restarts manufacturing of COVID-19 vaccine Covishield
Reacting to reports of COVID-19 vaccines shortage, he said manufacturers are ready but there has been no demand. "Just as a precaution, at risk we have done it so that people have a Covishield as a choice if they want it," Poonawalla told PTI on restarting of manufacturing of the vaccine.
Countries which chose Covishield fared better than those that took mRNA vax: Adar Poonawalla
Covovax, which is our Novavax product, is proven to be the best against Omicron and Omicron sub variants. It is also the only vaccine from India which is US and EMA approved, says Adar Poonawalla.
Govt likely to float global tender for HPV vaccine in April; Merck, Serum Institute may participate
India, at present, is fully dependent on foreign manufacturers for HPV vaccines. Globally, three foreign firms manufacture HPV vaccines out of which two sell their doses in India. Each dose of the vaccine available in the market costs more than Rs 4,000, sources said.
Vaccine for cervical cancer prevention to be available in small quantity in 2023, increased next year, says Adar Poonawalla
Poonawalla briefed Union Health Minister Mansukh Mandaviya about the HPV vaccine in the national capital.Speaking to after the meeting, the SII CEO said, "I had come to brief the Union Health minister about it. We'll wait for the government program to roll out. Capacity is very small this year but we'll build a large capacity to take care of the entire nation's needs for next year.
COVID-19: Covovax to get approval as booster in 10-15 days, says SII CEO Adar Poonawalla
Appealing to students who wished to pursue education abroad, he said there was no place like India to fulfil dreams due to the presence of institutions like Bharti Vidyapeeth and others.
Poonawalla Fincorp well capitalised to touch Rs 50,000 cr AUM in 5 years
"Going forward, we will only focus on organic growth in our current and proposed line of business. We will continue to build a strong retail franchise in consumer and MSME financing. We are already doing ₹1,200 crore of organic business per month," said Adar Poonawalla.
Adar Poonawalla-backed multibagger stock can rally up to 25%: Motilal Oswal
With huge growth opportunities for consumer and small business finance, the brokerage said that post-acquisition, PFL’s management has strengthened its foundation notably by investing in technology (aiding infrastructure/processes), distribution and talent.
No increase in demand for boosters yet: Poonawalla
"I have still not seen a surge for boosters. We have offered it (vaccine) to all hospitals and clinics but there has been a lukewarm response, not even 100,000 people per day are taking booster shots," Poonawalla said in an interview to ET. "That number should go up."
This Adar Poonawalla-backed NBFC becomes D-Street’s ‘darling’; can the tag last long?
The number of mutual funds holding the stock in their portfolio has doubled since May, data on Trendlyne showed. Aditya Birla Sun Life Small Cap Fund was the highest buyer of the shares of the NBFC in October.
Posing as Adar Poonawalla, scammers dupe SII of Rs 1 cr, 7 nabbed
As per the complaint, Satish Deshpande, one of the directors at the SII had received a message on WhatsApp from a person posing as SII CEO Adar Poonawalla and was asked to send money into seven different accounts in September 2022. Believing the message was from Poonawala, Deshpande transferred Rs 1.01 crore into those accounts, only to realise later that the company had been duped.
Over 200m doses of Covaxin set to expire
Millions of doses of Covaxin are set to expire early next year and may have to be dumped amid poor demand for Covid-19 vaccination in the country, a person in the know told ET.
HPV vaccine production delayed due to COVID focus, will start supply to Indian govt in early 2023: SII
Exports will have to wait till 2024, its chief executive Adar Poonawalla told reporters here on Thursday evening, adding that the company has to build a scale of manufacturing to over 150 million for that.
People fed up with Covid, no takers for boosters, SII not making Covishield since December 2021: Adar Poonawalla
According to the Serum CEO, booster vaccines have no demand because of the "general lethargy among people and also because they are fed up with the pandemic."
Poonawalla Fincorp disbursals rise by 44% to Rs 3,720cr in Jul-Sep
Total disbursements were Rs 3,720 crore on a consolidated basis in the year-ago quarter. Sequentially, disbursements rose by 8 per cent in the July-September quarter.
JetSynthesys to invest $50 million to build metaverse practice
As the first step towards this, the Adar Poonawalla and Kris Gopalakrishnan backed company announced the acquisition of Metaphy Labs, an end-to-end solution provider in the Web 3.0 space.
SII's Poonawalla makes clarion call for global certification of vaccines
"Multilateral organisations such as the United Nations and the World Trade Organisation should take it upon themselves to harmonise the certification of vaccines," he told PTI on the sideline of the conference, adding that "the world needs it if we want to be prepared in the future."
Fraudsters dupe Serum Institute of Rs 1 cr by asking for money transfer in CEO's name
Satish Deshpande, one of the directors of the SII, received WhatsApp messages from a person who posed as Adar Poonawalla, as per the FIR. The sender asked Deshpande to transfer money to certain bank accounts immediately, said the complaint filed by the finance manager of the firm. Believing that it was the CEO who had messaged, company officials transferred Rs 1,01,01,554 online, only to realize later that Poonawalla had never sent any such WhatsApp communication.
SII will try to launch Omicron-specific vaccine after six months: Adar Poonawalla
The Pune-based Serum Institute is working with US biotechnology major Novavax to bring the Omicron-specific vaccine. Omicron sub-variant of the COVID-19 was declared as a variant of concern by the World Health Organisation due to its fast transmission and infection rate.
Cervical cancer vaccine to be launched in few months at affordable price: SII CEO Adar Poonawalla
Poonawalla told reporters on the sidelines of the event, "The cervical cancer vaccine will be affordable and would be available in the range of Rs 200-400. However, the final price will be decided after detailed discussions with the government". "The vaccine would be much much less in price as compared to other vaccines for cervical cancer," he said.
Adar Poonawalla effect! Multibagger midcap stock rallies over 700% in 2 years
Domestic brokerage JM Financial, which initiated coverage on the stock with a Buy rating, values the stock at 4x Sep’24e P/BV to arrive at a target price of Rs 400. This signals an upside potential of up to 32 per cent.
Gautam Adani to address Forbes Global CEO Conference in Singapore
Adani will be making a keynote speech on the second day of the conference, where, to date, some 40 speakers have confirmed their participation. Among the speakers are Indian business leaders such as Ajay Banga, Vice Chairman of General Atlantic, Byju Raveendran, Founder and CEO of Byju's and Adar Poonawalla, CEO of Serum Institute of India.
SII is working on an Omicron-specific vaccine, may launch it by the end of this year: Report
SII Chief Executive Officer Adar Poonawalla told NDTV that the vaccine is being developed in collaboration with Novavax. Poonawalla further said that the vaccine will be specific to the BA5 sub-variant of Omicron.
Serum Institute in talks with Bavarian Nordic to import monkeypox vaccine
Danish firm Bavarian Nordic has already developed a vaccine against monkeypox and is available in different markets under brand names Jynneos, Imvamune or Imvanex.
All you need to know about the upcoming cervical cancer vaccine in India
To obtain a complete regimen of HPV vaccines in India, one must spend at least Rs 5,000 to Rs 8,000. A qHPV vaccine is available from Merck Sharp and Dohme (Gardasil), and a bivalent HPV vaccine is available from GSK (Cervarix).
India gets its first cervical cancer vaccine; women in their 30s remain vulnerable, must get regular check-ups done
Adar Poonawalla said that the 'affordable' qHPV will be launched later this year.
Vaccine giant Serum Institute of India plans African plant in global expansion
SII Chief Executive Adar Poonawalla said he was meeting some African officials in Davos to discuss his plans. Asked about possible investments, he said such projects typically required at least around $300 million.
Not just business at ET Awards: Serum CEO's shout-out to Daddy; Piramal ladies stand out for their sartorial sense
The gala award ceremony also saw some deals being 'cemented'.
ET Awards 2021: Honouring business world's best and brightest
The winners were felicitated in the presence of Ministers and top leaders of India Inc.
Covovax now available for children in India: Adar Poonawalla
In a post on Twitter, he said Covovax, which has been developed by Novavax, "is now available for children in India". He further said, "This is the only vaccine manufactured in India that is also sold in Europe and has an efficacy of > (more than) 90%."
Biocon Biologics may close $3.34 billion Viatris deal in Q1
Out of $2 billion, $800 million will come through equity infusion from existing investors including parent Biocon and others such as Serum Institute of India, Abu Dhabi-based ADQ.
Covishield offers longer immunity than mRNA jabs, says Adar Poonawalla
Poonawalla, ET's Business Leader Of the Year for 2021, was optimistic that final approvals for administering Covovax to children would come soon, giving a boost to India's immunisation programme for kids under the age of 18.
India's Covid management most transparent, says Adar Poonawalla
He said there are "global political forces at play", which want to criticize India and show India in the wrong light.
Adar Poonawalla recounts the challenges in producing India's first COVID vaccine
Poonawalla said he even looked at diluting a stake in Serum from private equity to raise the capital but they didn't need to do it because they went to other countries and philanthropists instead who understood the urgent need of doing it.
Adar Poonawalla blames government for delay in launch of his vaccine Covovax
"In Delhi over the last three months, what we are seeing is that we have gone back to the what I would say usual, normal processes business as usual where the urgency isn't there. There are the priorities. So, we are taking our time with approvals and that's where you see a lot of delays," he said at the Times Network's India Economic Conclave 2022 on Friday.
India is now better prepared to fight any Covid-19 variant, says SII's Adar Poonawalla
In an exclusive interview, Poonawalla said, "We are definitely far better prepared than we were in 2020. In 2020, we did not have the testing capabilities, the genomic sequencing. We didn't have any of that. We didn't have the hospital infrastructure that we have here today."
Appealed to govt to reduce booster gap to 6 months, says SII's Adar Poonawalla
“We have 200 million doses of Covishield lying with us and it is available for boosters. It is available for exports and we are slowly moving that out but bringing the gap from nine months to six months will definitely help hospitals and other clinics to administer the doses faster for boosters as we have got new mutant variants coming.”
Covishield, Covaxin price cut to Rs 225 per dose for private hospitals
The move, by the health ministry, came a day before precautionary doses are to be made available to everyone over the age of 18.
Low number of COVID-19 cases now as India chose right vaccine, says Serum Institute's Adar Poonawalla
Speaking on the booster dose, Poonawalla said, "About the booster dose, we have appealed to the government, because everyone who needs to travel, needs the booster dose. They (government) are having internal discussions and a policy on booster dose may be announced soon."
ET Business Leader of the Year 2021: Adar Poonawalla-A calculated bet that put India on the leaderboard of Covid fightback
When India was struck by the Covid-19 pandemic in March 2020, Poonawalla lost little time in stitching up an alliance with the Oxford University-AstraZeneca combine to license the vaccine it was developing and which it would eventually manufacture under the Covishield brand name.
Serum Institute seeks emergency use authorisation for its rBCG tuberculosis vaccine
The EUA application was submitted on March 22 by Prakash Kumar Singh, Director of Government and Regulatory Affairs at the Serum Institute of India (SII). India's TB immunisation programme currently offers BCG vaccination at birth or as early as possible till one year of age.
Adar Poonawalla hopes that Djokovic will change his mind on vaccines, says he respects tennis champ’s personal views
The CEO of Serum Institute of India took to Twitter to share his thoughts on the tennis player's views.
SII CEO Adar Poonawalla urges Novak Djokovic to get vaccinated against COVID-19
Last month, Djokovic was prevented from participating in the Australian Open tournament due to his unvaccinated status. The 34-year-old tennis superstar was detained and eventually deported from Australia for failing to meet that country's strict vaccination requirements.
Mylab partners with Shilpa Biologicals to enter vaccines & therapeutics segment
Adar Poonawalla-backed Mylab plans to develop world-class diagnostics, vaccines and therapeutics to augment its presence in the healthcare market. The company will leverage the technical expertise of Shilpa Biologicals in development and manufacture of biopharmaceuticals through its facility at Dharwad.
A Budget booster shot for the ‘pharmacy to the world’
The announcements made are preventive and curative, benefiting the people of the community. An open platform for the National Digital Health Ecosystem will make access to health and wellness more equitable.
Serum Institute of India applies for full market authorisation for Covishield
Covishield has been one of the main vaccines used in India for Covid-19. Around 90% people in India have got Covishield. The vaccine was granted Emergency Use Authorisation (EUA) in January last year.
Adar Poonawalla picks up 20% stake in JetSynthesys' Wakau
Wakau is a community-driven social media platform that offers a combination of mobile-first screen experience and short-video content in the entertainment and fashion domains, with an associated video-commerce element.
Serum Institute of India hopes to launch Novavax Covid-19 vaccine for children in six months
The Novavax shot, which the world's largest producer of vaccines calls Covovax, has shown good results in trials in children aged three and older, Adar Poonawalla told a virtual conference organised by the Confederation of Indian Industry.
Vaccine company’s plan to cut output won't hit supply, says top govt official
According to the health ministry more than 139 crore vaccine doses have been provided to states and UTs so far through the central government as on December 8.
Suresh Jadhav, key executive of SII & doyen of vaccine industry, passed away
Jadhav has been with SII for over four decades, playing a crucial role in building SII as the world's largest vaccine producer. As part of the top leadership at SII, Jadhav has been a guiding force, as the drug maker rushed ahead to produce COVID-19 vaccine Covishield.
SII may cut Covishield's monthly production by half amid demand slump
SII has written to the government to seek clarity on its requirement, if any, for normal two doses for eligible people in the country and also on booster doses.
Vaccine hesitancy greatest threat in beating the pandemic: Adar Poonawalla
Union health minister Mansukh Mandaviya, too, on Wednesday appealed all eligible citizens to get vaccinated, even as he said the number of fully jabbed surpassed partially vaccinated people. "We will win the battle against Covid-19 together," he tweeted.
Vaccine hesitancy greatest threat in overcoming Covid: Adar Poonawalla
The cumulative COVID-19 vaccines administered in the country has exceeded 113.68 crore mark. Of all the vaccine doses administered, around 90 per cent are Serum’s Covishield and close to 10 per cent are Bharat Biotech’s Covaxin.
Serum Institute looks to supply 25 million doses to Covax till December
The Covax facility was created last year to ensure Covid vaccines were made available around the world, with richer countries subsidising costs for poorer nations.
Covovax nod expected by January, data to be submitted soon, says SII Chief
The drug regulator had earlier asked the company - which had applied for emergency use authorisation (SII) for Covovax in August - to submit immunogenicity data.
After one year, people might look at Covid vaccine only as a booster: Adar Poonawalla
Adar Poonawalla, chief executive officer of Serum Institute of India, shares his journey and how his company overcame a plethora of challenges to reach the 1 billion vaccine does milestone
We did what we had to do for our nation and now hope to make profit from exports: Adar Poonawalla
“We priced our vaccine in conjunction with the government. Most of it was at Rs 200 which the government was buying it for. We hardly sold anything in the private market because as everyone was getting it for free, no one wanted to pay for it. ”
Serum Institute could export 20-30 million vaccine doses a month to COVAX: Adar Poonawalla
Adar Poonawalla said the company's production of the vaccine could go up to 240 million doses a month from around 220 million now.
Wellness Forever files DRHP for Rs 1500 crore IPO
The IPO consists of a fresh issue of equity shares up to Rs 400 crore and an offer for sale up to 1.60 crore equity shares, according to DRHP.
Abhay Bhutada hasn't done anything as per lawyers, says Adar Poonawalla
Earlier, Sebi barred Bhutada and seven other entities from the securities market for insider trading. The regulator also ordered impounding of wrongful gains worth over Rs 13 crore, through an interim order. In February 2021, Sebi's system-generated insider trading alerts related to the company's shares.
Biocon Biologics, Serum Institute Life Sciences to expand tie-up for R&D, new vaccines
On Thursday, Biocon had said it will offer around 15 per cent stake to Serum Institute Life Sciences at a post-money valuation of about Rs36000 crore ($4.9 billion) where 15% will be valued at about Rs5100 crore. Post transaction, Biocon Ltd will hold 74.89% stake in Biocon Biologics. Serum Institute Life Sciences (SILS) is a subsidiary of Serum Institute of India (SII).
Kiran Mazumdar-Shaw & Adar Poonawalla spell out the road map for Biocon-Serum alliance
"The Biocon-Serum alliance will initially focus on Covid vaccines, because that is the need of the hour. At a later stage, we will see what makes the most global impact, what has the most value. After that, we'll jointly decide on what those vaccines should be."
Load more news